Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus
The purpose of this study is to find out more information about patients who have cancer (adenocarcinoma) of the esophagus or gastroesophageal junction (GEJ) who have been treated with chemotherapy and radiation but have not had surgery. The study will follow patients for 5 years to monitor for their cancer and to see how the standard medical care affects the daily life of patients.
Adenocarcinoma Esophagus
OTHER: Observational
Progression free survival, 5 years
Overall survival, 5 years|Rate of complete remission, 8 weeks after completion of neoadjuvant chemoradiotherapy|Occurrence of local recurrence or mestastasis or both, 5 years|Adverse effect profile, 5 years
The purpose of this study is to find out more information about patients who have cancer (adenocarcinoma) of the esophagus or gastroesophageal junction (GEJ) who have been treated with chemotherapy and radiation but have not had surgery. The study will follow patients for 5 years to monitor for their cancer and to see how the standard medical care affects the daily life of patients.